Committees
Memberships and roles in committees:
National level:
International level:
WG3: Adverse effects/Risk-Benefit analysis
WG5: Communication and dissemination
BioNanoNet is member of the Management Committee in COST-Action CA15107 MULTICOMP.
MC-Member: Christa Schimpel
MC-Substitute: Susanne Resch
WG3: Characterization, Health, Safety and Environment (HSE)
BioNanoNet is member of the Management Committee in COST-Action TD1402 RADIOMAG.
MC-Member: Christa Schimpel
COST Action CA17140 is the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies.
By promoting scientific exchanges, technological implementation and innovative solutions, the Action will provide a timely instrument to rationalize and focus research efforts at the EU level in dealing with the grand challenge of nanomedicine translation in cancer, one of the major and societal-burdening human pathologies.
BioNanoNet is member of the Management Committee in COST-Action CA17140 Nano2Clinic.
MC-Member: Andreas Falk
MC-Substitute: Susanne Resch
BioNanoNet is member of the Management Committee in COST-Action MP1404 SimInhale
MC-Member: Eleonore Fröhlich
MC-Substitute: Christa Schimpel
WG4: Advanced imaging, patient monitoring and delivery verification
WG5: Toxicity, xenobiotics, risk assessment and policy development
BioNanoNet is member of the Management Committee in COST-Action CM1403 UPCON.
MC-Member: Andreas Falk
MC-Substitute: Christa Schimpel
http://www.cost.eu/COST_Actions/cmst/CM1403
Download 
final COST Action CM1403 Report
As part of European Technology Platform Sustainable Chemistry (SusChem) BioNanoNet supports the strategic development (e.g. in the field of process technologies, digital technologies) on European level, as well as on national level by coordinating the Austrian national technology platform SusChem-AT. Both activities are linked to the respective governmental parts, the European Commission on European level; the Austrian ministries on national level, and the provincal government (e.g. Styria) on regional level.
In addition to the sustainable chemistry activities, BioNanoNet also supports the further development of the sensortechnology field in Austria and Europe (e.g. EU-FP7-project SPIDIMAN; EU-H2020-project R2R Biofluidics). One initiative which combines regional with national experts to close gaps along the value chain and to support industrial innovation is the Austrian Microfluidics Initiative, also coordinated by the DIH BioNanoNet. For further information, please see https://www.bionanonet.at/austrian-microfluidics-initiative.
The European Society for Nanomedicine is a society of individuals and bodies across Europe that focuses on the clinical application of nanomedicine and its implications for individuals and society. Through this focus, it complements a number of already existing European platforms, initiatives, and framework-programmes that see their main task in linking researchers and industry.
The ETPN is an important European Technology Platform that contributes to the advancement nanomedicine in Europe.
BioNanoNet is member of the Executive Board of the ETPN and chair of the working group on safety and characterisation in nanomedicine (former WG toxicology and characterisation).
BioNanoNet is coordinator of the Austrian national technology platform NanoMedicine-Austria. Further information: https://www.bionanonet.at/testseite/national-technology-platforms/nanomedicine-austria
BioNanoNet is member of the General Board of the NANOfutures a.s.b.l. and is a member of several working groups that are part of this network, active world-wide.
All Nanosafety-relevant European projects are connected to each other in the NanoSafetyCluster (NSC).
BioNanoNet is member of the Coordination Team.
The coordination team consist of Eva Valsami-Jones (University of Birmingham, UK; coordinator), Iseult Lynch (University of Birmingham, UK), Andreas Falk (BioNanoNet BioNanoNet Forschungsgesellschaft, Graz) and Flemming Cassee (National Institute for Public Health and the Environment RIVM, Bilthoven, Netherlands). The team will get secretarial support via H2020 project ACEnano for the coming years.
The role of the Coordination team is to:
- Support for WGs and TFs, communication group and Innovation Governance
- Facilitate key NSC decisions via online voting to enhance member participation
- Facilitate enhanced transparency around membership of WGs and cluster activities
- Support to the NSC projects for implementation of Core activity, and where no project available to sponsor a Core activity the Coordination team will bridge the gap.
- Organization of biannual NSC plenary meetings (which will be mainly hands-on events designed to build consensus on key topics) as well as providing updates to the wider NSC membership , including preparation of agendas together with Steering group and the Commission
- Preparation of the minutes from meetings of Steering group and NSC plenary meeting
- Maintaining communication between members of the Steering group, WGs, TFs, CoRs,
- Conducting special tasks such as publishing NSC documents, liaising with EC4SafeNano, etc.
- Supporting the development of the strategy for the transition to an innovation governance platform.